Proxy Results Form 8 K

ITEM 5.07 SUBMISSION OF A MATTER TO A VOTE OF SECURITY HOLDERS.

On September 12, 2024, MIRA Pharmaceuticals, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "Annual Meeting"). The record date for stockholders entitled to notice of, and to vote at, the Annual Meeting was July 22, 2024 (the "Record Date"). As of the Record Date, there were 14,780,885 shares of common stock, par value $0.0001 per share ("Common Stock") of the Company outstanding. Each share of the Company's Common Stock represents one vote that could be voted on each matter that came before the Annual Meeting.

At the Annual Meeting, 9,418,088 shares of Common Stock were represented and voted by proxy, constituting a quorum for the Annual Meeting (the 9,418,088 votes represented equaled approximately 63.72% of the outstanding possible votes).

At the Annual Meeting, five proposals were submitted to the Company's stockholders. The proposals are described in more detail in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on July 26, 2024. The final voting results were as follows:

Proposal 1

The Company's stockholders elected Erez Aminov, Michael Jerman, Matthew Del Giudice, M.D., Denil Nanji Shekhat, M.D., and Edward MacPherson as directors of the Company to serve until the next Annual Meeting of Stockholders.

Nominee		Votes For		Votes Against		Votes Abstained		Broker Non-votes
Erez Aminov		6,630,277		-		1,149,850		1,637,961
Michael Jerman		6,629,358		-		1,150,769		1,637,961
Matthew Del Giudice, M.D.		6,629,198		-		1,150,929		1,637,961
Denil Nanji Shekhat, M.D.		6,630,735		-		1,149,392		1,637,961
Edward MacPherson		6,630,734		-		1,149,393		1,637,961

Proposal 2

To ratify the appointment of Cherry Bekaert LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024.

Votes For		Votes Against		Votes Abstained		Broker Non-votes
9,408,950		609		8,529		-

Proposal 3

To approve certain amendments to the 2022 Omnibus Incentive Plan (the "Plan") to increase the number of shares available under the Plan.

Votes For		Votes Against		Votes Abstained		Broker Non-votes
6,571,765		1,195,156		13,206		1,637,961

Proposal 4

The proposal to approve an adjournment of the Annual Meeting, if necessary, to solicit additional proxies if there are not sufficient votes in favor of Proposals 1 and/or 3 was withdrawn because the Company's stockholders approved and adopted the Proposal 1 and 3, as noted above.

Votes For		Votes Against		Votes Abstained		Broker Non-votes
9,348,608		59,780		9,700		-

Public link

Please use the above public link if you want to share this noodl on another website.